Azacitidine - Generic Drug Details

What are the generic sources for azacitidine and what is the scope of patent protection?

Azacitidine is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Actavis Llc, Amneal, Cipla, Dr Reddys, Eugia Pharma, Eurohlth Intl Sarl, Hetero Labs Ltd Vi, Jiangsu Hansoh Pharm, Lupin, Meitheal, Msn Labs Pvt Ltd, Natco Pharma Ltd, Pharmobedient, Reliance Life, Shilpa Medicare, Bristol-myers, and Bristol, and is included in eighteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Azacitidine has one hundred and two patent family members in thirty-five countries.

There are fifteen drug master file entries for azacitidine. Twenty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for azacitidine

International Patents:	102
US Patents:	3
Tradenames:	3
Applicants:	18
NDAs:	18
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	723
Patent Applications:	5,766
Drug Prices:	Drug price trends for azacitidine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for azacitidine
What excipients (inactive ingredients) are in azacitidine?	azacitidine excipients list
DailyMed Link:	azacitidine at DailyMed

See drug prices for azacitidine

Recent Clinical Trials for azacitidine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prajwal Dhakal	PHASE2
Stemline Therapeutics, Inc.	PHASE1
Swedish Orphan Biovitrum	PHASE2

See all azacitidine clinical trials

Generic filers with tentative approvals for AZACITIDINE

Applicant	Application No.	Strength	Dosage Form
		300MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for azacitidine

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

Medical Subject Heading (MeSH) Categories for azacitidine

Antimetabolites, Antineoplastic

Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for azacitidine

L01BC	Pyrimidine analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for AZACITIDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ONUREG	Tablets	azacitidine	200 mg and 300 mg	214120	1	2021-09-30

US Patents and Regulatory Information for azacitidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eurohlth Intl Sarl	AZACITIDINE	azacitidine	POWDER;INTRAVENOUS, SUBCUTANEOUS	209337-001	Jun 8, 2020	AP	RX	No	No
Meitheal	AZACITIDINE	azacitidine	POWDER;INTRAVENOUS, SUBCUTANEOUS	212128-001	Nov 2, 2020	AP	RX	No	No
Bristol	ONUREG	azacitidine	TABLET;ORAL	214120-001	Sep 1, 2020		RX	Yes	No	12,053,482
Shilpa Medicare	AZACITIDINE	azacitidine	POWDER;INTRAVENOUS, SUBCUTANEOUS	207518-001	Sep 29, 2016	AP	RX	No	No

EU/EMA Drug Approvals for azacitidine

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Vidaza	azacitidine	EMEA/H/C/000978Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification.	Authorised	no	no	no	2008-12-17
Accord Healthcare S.L.U.	Azacitidine Accord	azacitidine	EMEA/H/C/005147Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),- chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,- acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,- AML with >30% marrow blasts according to the WHO classification.	Authorised	yes	no	no	2020-02-13
Mylan Ireland Limited	Azacitidine Mylan	azacitidine	EMEA/H/C/004984Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification.	Authorised	yes	no	no	2020-03-27
betapharm Arzneimittel GmbH	Azacitidine betapharm	azacitidine	EMEA/H/C/005075Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 % to 30 % blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification,AML with > 30 % marrow blasts according to the WHO classification.	Authorised	yes	no	no	2020-03-24

International Patents for azacitidine

Country	Patent Number	Title	Estimated Expiration
Argentina	071808	FORMULACIONES ORALES DE ANALOGOS DE CITIDINA, METODO DE TRATAMIENTO, COMPOSICION FARMACEUTICA Y USO
Australia	2009246926	Oral formulations of cytidine analogs and methods of use thereof
Australia	2013202665	ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
Australia	2015202884	ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF

Azacitidine Market Dynamics and Financial Trajectory: Revenue Drivers, Competition, and Patent/Exclusivity-Led Risk for Nucleoside Antimetabolites (2025–2030)

Last updated: June 20, 2026

Azacitidine is a high-value oncology standard of care with revenue supported by (1) core use in MDS and AML, (2) sustained dosing adoption in real-world practice, and (3) life-cycle expansion via combination regimens and line-of-therapy sequencing. Financial trajectory is increasingly shaped by biosimilar and generic entry risk in markets where approvals and patent positions allow earlier price erosion, while premium pricing and payor access remain important in geographies with limited competition.

What patents protect azacitidine and how do they impact generic or biosimilar entry risk?

Azacitidine is primarily marketed as branded products in major markets, and the competitive threat is driven by whether follow-on manufacturers can clear regulatory approval and patent obstacles for the specific dosage forms and manufacturing processes.

Which azacitidine active patents typically control exclusivity?

Patent estates for azacitidine generally cluster into:

• Composition of matter and nucleoside analog claims
• Formulation patents (stability, lyophilization or wet product process, sterile fill considerations)
• Method-of-use patents (MDS, AML, transplant-ineligible AML, dosing schedules)
• Process/manufacturing patents (chemical synthesis steps, purification, impurity control)

How does patent timing map to financial trajectory?

Revenue trajectories for azacitidine usually show “step changes” around:

• First meaningful price pressure when a second-source product is launched
• Anticipated further erosion at subsequent line expansions or when payors shift toward lower net prices
• Localized volatility based on settlement timelines and early-launch decisions

Key commercial risk variables

• Whether follow-on entrants target the same route (subcutaneous vs intravenous) and dosage strengths
• Whether Orange Book-like listings (US) or EU SPC-linked exclusivity (where applicable) constrain approvals
• Settlement terms that convert litigation risk into delayed entry or shared market access

When does azacitidine lose exclusivity and what are the practical launch timelines for generics?

Financial trajectory depends on when exclusivity ends in each market and on whether entrants face successful Paragraph IV or national-phase litigation.

US market timing mechanics

In the US, “loss of exclusivity” typically translates into:

• Orange Book-listed patents expiring or being carved out via settlement
• Litigation outcomes delaying FDA approval or launch
• Supply readiness and labeling readiness affecting actual revenue impact

EU and UK timing mechanics

In the EU/UK, practical launch timing is often governed by:

• Regulatory data protection and any supplementary protection certificates (SPCs) tied to the branded reference product
• Manufacturing and formulation continuity between reference and follow-on

Why timeline matters financially

Azacitidine is dosed across large patient populations over long horizons, so:

• Even modest early competition can produce large cumulative revenue losses
• Conversely, delayed competition can sustain pricing and volume together longer

How many patents cover azacitidine formulations and delivery methods (IV vs SC) that drive pricing?

For market dynamics, the most commercially relevant “IP perimeter” is the one that limits interchangeable substitution for payors.

Formulation and device-related constraints

Follow-on competition can be slowed if patents cover:

• Stability and reconstitution instructions
• Particle profile and impurity thresholds
• Sterile manufacturing process steps that affect lot release and shelf-life
• Packaging and dosing device specifics that create non-interchangeability

Route-of-administration differentiation

Azacitidine is commonly used in regimens that include subcutaneous dosing. If an entrant launches only one route or one dosing schedule, payors may restrict interchangeability, reducing immediate revenue erosion.

What is the Orange Book status of azacitidine and where are generic entry risks highest?

Orange Book status determines whether a generic manufacturer faces patent-listed obstacles, which in turn shapes expected launch date windows.

Entry-risk pattern that affects revenues

• High risk: multiple unexpired method-of-use and formulation patents plus active litigation
• Medium risk: fewer remaining patents or settlements that reduce uncertainty
• Lower risk: patents nearing expiration or no viable barriers for the specific product presentation

How this shows up in financial results

Companies with azacitidine portfolios typically protect net price through:

• Brand loyalty, reimbursement support, and access agreements
• Litigation-anchored delay of first meaningful price pressure When those barriers drop, revenue often declines faster than volume alone would predict due to switching and rebate rebalancing.

What patent litigation affects azacitidine pricing and market share?

Litigation affects both:

• “Launch certainty” for challengers
• “Net price certainty” for incumbents

Typical litigation pathways

• US patent challenges tied to Orange Book-listed patents
• Settlement agreements that allow earlier launch in exchange for license fees or agreed carve-outs
• Court rulings that narrow the patent scope but still delay launch due to remaining patents

Commercial outcome linkage

Litigation outcomes often map to:

• A binary market-shift event (launch vs no launch in a quarter)
• Multi-quarter “pricing band” erosion as payors test net-cost differences across contracting cycles

How does azacitidine compare with decitabine and other hypomethylating agents in competitive dynamics?

Azacitidine competes within the hypomethylating agent (HMA) class where payor and provider decisions hinge on:

• clinical outcomes for specific subpopulations
• regimen convenience and dosing preference
• access programs and net pricing

Class competition effects

If an HMA brand experiences earlier follow-on entry than azacitidine, payors may shift supply allocation, compressing premium pricing across the class. Conversely, if azacitidine remains more protected longer, it can retain a relatively stronger net price until category switching occurs.

Combination regimen competitiveness

Combination HMAs and HMA-based regimens (for example, with targeted agents or venetoclax-like strategy frameworks in AML contexts) can:

• preserve azacitidine demand when partners can maintain regimen efficacy and access
• shift incremental demand toward the protected backbone if IP or reimbursement supports regimen standardization

What formulations are protected for azacitidine and how do they influence biosimilar substitution?

Azacitidine is a small-molecule nucleoside analog. “Biosimilar” framing is more common for biologics, but competitive substitution concerns remain for:

• generic formulations
• route-specific equivalents
• manufacturing process changes that affect impurity profiles and stability

Substitution friction that can slow price erosion

Follow-ons may experience slower uptake if:

• labeling and dosing instructions reduce perceived interchangeability
• stability and reconstitution constraints increase administration burden
• payors require prior authorization, delaying conversion

Which companies are challenging azacitidine and what is the likely settlement-driven market impact?

Competitive market impact depends on challenger count, litigation posture, and timing. The most revenue-relevant signals are:

• number of filed ANDA challenges (US)
• number of follow-on labels launched by region
• whether settlements include “agreed launch dates”

How strong is the patent estate for azacitidine by jurisdiction and dosage form?

Patent strength translates into practical exclusivity as measured by:

• number of unexpired patents on relevant presentations
• whether method-of-use patents cover core regimens
• whether formulation patents restrict interchangeable substitution

What drives stronger estates commercially

• Method-of-use patents covering dominant real-world regimens
• Multiple overlapping formulation/process patents
• Injunction risk during active litigation

What weakens estates commercially

• Narrow claim scope and adverse claim construction
• settlements that permit early entry even while some patents remain
• patent expiry windows that are close enough to create “launch anticipation” even before final expiry

What generic entry risks exist for azacitidine in the US and EU and how fast does price erosion occur?

US price erosion pattern

When a second-source or generic launches:

• incumbents typically hold list price but lose net price via increased competition rebates and contracting
• volume often shifts quickly if payer formularies allow substitution

EU price erosion pattern

In EU markets, price erosion often depends on:

• national tender rules
• switching restrictions tied to procurement specifications
• negotiated reimbursement

Speed of revenue impact

Azacitidine revenue is high-frequency dosing and usually declines in stepwise fashion around:

• formulary updates
• tender cycles
• first wave of substitution during the first 1 to 3 quarters post-launch

What FDA pathway status drives azacitidine market access for generics?

FDA pathway and submission class influence timing:

• ANDA approvals depend on patent certifications and litigation outcomes
• labeling changes and bioequivalence evidence influence whether substitution is automatic or requires additional steps

Relevance to financial trajectory

Even if ANDA approval occurs, commercial revenue impact depends on:

• whether products are stocked by wholesalers and administered by oncology centers
• whether payors cover the competing product without delays
• whether the incumbent retains privileged contracting

How does azacitidine revenue performance typically evolve across the product life cycle?

A standard life-cycle pattern for high-value oncology injectables:

1. Initial growth period driven by expanding indications and physician adoption
2. Steady-state maintenance with contracting and steady patient throughput
3. Pre-generic pricing stability as launches near but are blocked by patent and litigation
4. Step-down after first meaningful market entry
5. Secondary erosion as additional entrants and supply scale increase competitive intensity

Financial trajectory checkpoints: what investors and strategists watch in azacitidine

High-signal indicators:

• net revenue growth vs unit volume growth (net price vs demand mix)
• payer reimbursement changes and formulary status
• mix shift between routes (IV to SC) and dosing schedules
• region-by-region contracting and tender results
• oncology center adoption rates for follow-on products post-approval

Revenue sensitivity drivers

• Dose intensity and persistence (time on therapy)
• Patient population expansion in MDS and AML subgroups
• Treatment sequencing and regimen substitution by competing HMAs and combinations
• Supply chain resilience and manufacturing scalability (to avoid “competitive demand without supply” scenarios)

Key Takeaways

• Azacitidine’s financial trajectory is driven by sustained demand in MDS and AML and shaped by payor net-price behavior more than list price.
• Patent estate strength and jurisdictional exclusivity windows determine whether competition emerges as a delayed “step event” or earlier gradual erosion.
• Formulation and route-of-administration protections can slow interchangeability, extending premium net pricing.
• Litigation and settlements are the most practical gating mechanisms for generic timing in the US and procurement-driven entry timing in the EU.
• Monitoring net revenue vs unit volume, regional tender dynamics, and formulary substitution timing is the highest-leverage approach to forecast revenue direction.

FAQs

1. Does subcutaneous azacitidine face different substitution risk than intravenous azacitidine?
2. How do method-of-use patents for MDS and AML regimens affect generic launch timing?
3. What commercial indicators best predict whether azacitidine will see rapid net-price erosion after first entry?
4. How does tender-based procurement in Europe change the speed of azacitidine price decline?
5. When combination regimens expand, do they preserve azacitidine demand or shift share to alternative backbones?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. (n.d.). Paragraph IV certifications and generic drug review pathway overview. U.S. Food and Drug Administration. https://www.fda.gov/
3. European Medicines Agency. (n.d.). Regulatory science and market authorization guidance. European Medicines Agency. https://www.ema.europa.eu/